Back Pain News and Research

Latest Back Pain News and Research

New findings may make morphine a safer, more effective drug for chronic pain control

An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.

25 Mar 2011

FDA approves Boston Scientific's Clik Anchor for Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Clik™ Anchor for its Precision Plus™ Spinal Cord Stimulator (SCS) System, the world's first rechargeable SCS device for chronic pain management. The Clik Anchor features an innovative locking system designed to improve lead anchoring speed and consistency.

25 Mar 2011

Study: Surgeon enthusiasm linked to high spinal procedure rates

Surgeons in some areas are more likely to recommend surgery for low back problems—and those differences in "surgeon enthusiasm" are a major factor driving regional variations in spinal surgery rates, suggests a study in the March 14 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

25 Mar 2011

Little evidence supporting effectiveness of acupuncture in reducing pain

Although acupuncture is commonly used for pain control, doubts about its effectiveness and safety remain. Investigators from the Universities of Exeter & Plymouth (Exeter, UK) and the Korea Institute of Oriental Medicine (Daejeon, South Korea) critically evaluated systematic reviews of acupuncture as a treatment of pain in order to explore this question.

24 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

$Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty$

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

Medtronic of Canada Ltd. today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients.

23 Mar 2011

Artificial disc replacement may provide better long-term results at reduced cost

When physical therapy and drugs fail to relieve back or neck pain, patients often turn to spinal fusion surgery as a last resort, but two new studies show that in certain situations, especially when several discs are involved, artificial disc replacement may give better long-term results at lower cost.

23 Mar 2011

Ibuprofen - painkiller toxicity warning

In a recent development, doctors have warned regarding the possibly toxicities of common pain killer Ibuprofen adding that it can lead to a potentially fatal condition which can be triggered, in rare cases, by even a standard dose. The condition in question is called renal tubular acidosis (RTA). The research is published in the Medical Journal of Australia.

21 Mar 2011

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya, has received Notice of Compliance in Canada.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Shares of Bacterin's common stock receive approval for listing on NYSE Amex

Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that its common stock has been approved for listing on the NYSE Amex and has chosen Knight Capital Group as its designated market maker.

5 Mar 2011

Results Physiotherapy opens new clinic in Collierville

Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.

4 Mar 2011

FDA approves roflumilast to treat COPD

The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups or worsening of symptoms from severe chronic obstructive pulmonary disease.

1 Mar 2011

New drug approved for COPD by the FDA

The U.S. FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD). COPD affects smokers and the elderly and leads to severe difficulty in breathing, chronic cough and excessive mucus production. An exacerbation can last up to several weeks and result in a decline in lung function and increased risk of death, and it may be associated with severe anxiety, the FDA says.

1 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

Researchers combine old bones and new technology to treat chronic back pain

The bones of people who died up to a hundred years ago are being used in the development of new treatments for chronic back pain. It is the first time old bones have been used in this way.

1 Mar 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today.

28 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Back Pain News and Research

Latest Back Pain News and Research

New findings may make morphine a safer, more effective drug for chronic pain control

FDA approves Boston Scientific's Clik Anchor for Precision Plus Spinal Cord Stimulator System

Study: Surgeon enthusiasm linked to high spinal procedure rates

Little evidence supporting effectiveness of acupuncture in reducing pain

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

Artificial disc replacement may provide better long-term results at reduced cost

Ibuprofen - painkiller toxicity warning

Novartis new MS treatment receives Notice of Compliance in Canada

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Shares of Bacterin's common stock receive approval for listing on NYSE Amex

Results Physiotherapy opens new clinic in Collierville

FDA approves roflumilast to treat COPD

New drug approved for COPD by the FDA

FDA approves Forest Labs' Daliresp to treat COPD

Researchers combine old bones and new technology to treat chronic back pain

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Back Pain News and Research

Latest Back Pain News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in